Made possible by a charitable contribution from Bayer
Navigation Tip: Click on blue text that’s italicized, underlined and in bold for link to more information.


We hope that you’re doing well and enjoying the holiday season. This distribution of Prostate Cancer News You Can Use includes information below that may be of interest to you. Titles of prostate cancer news articles are also listed with a link to the Us TOO web page that provides access to the full text for each article.

If you’ve already contributed to the  Us TOO Holiday Hope fundraising campaign , thank you so much ! And if you’ve not yet done so,  PLEASE DONATE   to help support the work that we do at Us TOO providing educational resources, support services and personal connections to the prostate cancer community at no charge. 
In addition to volunteering his leadership with the Us TOO prostate cancer support group in Las Vegas, Tony Crispino has been working with ASCO (American Society of Clinical Oncology) over the last year on molecular biomarkers for prostate cancer , which has led to the release of a new guideline featured in the Journal of Clinical Oncology . This content helps address questions about the use of molecular tests in the treatment of prostate cancer. Thank you, Tony!

Rick Davis and our friends at AnCan are launching a new peer-led virtual group for Under-60 Men with Advanced Prostate Cancer. The group meets the 2nd Thursday of every month at 7:00 pm Eastern. In the U.S., join the conference call by dialing (646) 749-3129 , and use access code: 222-583-973 ; for international phone numbers and more information CLICK HERE .

On behalf of a market research company, Us TOO is providing a paid survey opportunity for prostate cancer patients and caregivers with advancing disease . Qualified respondents who complete the survey in its entirety will be eligible to receive $50 from the market research company paid via check within four weeks. The survey should take no longer than 20-25 minutes to complete. Please note, you will need to finish this study in one sitting. If you do not, please wait for an email from Elizabeth Lawson with a unique link to continue where you left off in the survey. The company will also make a donation to Us TOO. This is for US residents only at this time. CLICK HERE to take the survey.

If you have not already viewed video from our Prostate Cancer Pathways Detroit Event and Webcast, we invite you to check out the video . Links provide direct access to specific topics quickly and easily. We also have video of our Chicago event which will be made available within the next week or so; stay tuned!


Please note that the content below lists only the title of the article rather than a direct link to the content. For access to the full article  CLICK HERE .

  • Receiving care in a multidisciplinary prostate cancer clinic increases discussion about treatment options and adherence to national guidelines

  • FDA approves Pfizer and Astellas Pharmas prostate cancer drug

  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

  • New technique could optimize PSMA-targeted prostate cancer therapy

  • Findings from Department of Urology Provides New Data about Prostate Cancer (Spared Collaboration: Patient Selection for Partial Gland Ablation In Men With Localized Prostate Cancer)

  • Data on Prostate Cancer Reported by Researchers at University of Delaware (Smoking History, Intensity, and Duration and Risk of Prostate Cancer Recurrence Among Men With Prostate Cancer Who Received Definitive Treatment)

  • Colorado study suggests new strategies against bone metastases from prostate cancer

  • Being active reduces risk of prostate cancer

  • Reports Outline Prostate Cancer Findings from University of British Columbia (Facilitators and barriers to participation in lifestyle modification for men with prostate cancer: A scoping review)

  • Research from German Cancer Research Center Yields New Findings on Prostatectomy (Dosimetric Impact of Interfractional Variations for Post-prostatectomy Radiotherapy to the Prostatic Fossa-Relevance for the Frequency of Position Verification ...)

  • Home urine test for prostate cancer could revolutionize diagnosis

  • New, non-hormonal target identified for advanced prostate cancer


CLINICAL TRIAL - The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer. Get More Information or find more Details on .

CLINICAL TRIAL - Janssen Research & Development is seeking men in the US to participate in a clinical trial of an oral investigational medication for prostate cancer. All participants will receive daily investigational medication. To learn more about the Galahad study and find out if you may be eligible, get Details on . (Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.)

We wish you a wonderful holiday season and New Year! Watch for the January 2020 issue of the Us TOO  Hot SHEET  newsletter, and let us know how we can help provide you with educational resources, support services and personal connections to others in the prostate cancer community.

All the best,

Chuck Strand, Chief Executive Officer
James Hutson, Development Director
Jackie Konieczka, Office Manager
Terri Likowski, Program Director - Support Group Services
Tim Mix, Communications Director